drugset / Trial / NCT02009618

The Effects of Rifaximin Therapy in Irritable Bowel Syndrome

NCT02009618

Completed 500 enrolled Bezmialem Vakif University
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy of Rifaximin therapy started prior to completion of advanced examination procedure (before colonoscopy) of patients pre-diagnosed with irritable bowel syndrome, and implement it into clinical practice.

Timeline

Start
2013-01
Primary completion
2013-10
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifaximin Other / unclassified 1200 mg